Want to see HK:2500 full AI Analyst Report?
Venus Medtech (Hangzhou), Inc. Class H (2500) AI Stock Analysis
Venus Medtech (Hangzhou), Inc. Class H
(HKEX:2500)
Persistent losses and cash burn are the primary weaknesses, reinforced by broadly bearish technical positioning and an unfavorable negative P/E. Low leverage and a solid equity base provide limited offset.
Venus Medtech (Hangzhou), Inc. Class H (2500) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 429.14M
- Dividend Yield
- ―
- Average Volume (3M)
- 614.49K
- Price to Earnings (P/E)
- -0.8
- Beta (1Y)
- 0.57
- Revenue Growth
- -38.15%
- EPS Growth
- 25.70%
- Country
- Hong Kong
- Employees
- 557
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Specialties
Venus Medtech (Hangzhou), Inc. Class H Business Overview & Revenue Model
Company Description
Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. The company’s offers transcatheter aortic heart valve re...
How the Company Makes Money
The company primarily makes money by selling structural heart interventional medical devices to hospitals and healthcare providers, generating revenue from product sales associated with transcatheter valve procedures and related accessories/consumabl...
Venus Medtech (Hangzhou), Inc. Class H Financial Statement Overview
Summary
Persistent net losses, negative margins, and sustained cash burn weigh heavily on performance. Low leverage, a substantial equity base, and solid gross margins provide partial support.
Income Statement
25NegativeBalance Sheet
65PositiveCash Flow
35Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 255.30M | 306.79M | 470.83M | 491.37M | 406.46M | 415.86M |
| Gross Profit | 135.57M | 211.83M | 367.75M | 389.20M | 314.00M | 324.34M |
| EBITDA | -250.75M | -247.99M | -612.96M | -547.84M | -999.37M | -324.03M |
| Net Income | -464.44M | -407.69M | -714.31M | -703.75M | -1.06B | -373.64M |
Balance Sheet | ||||||
| Total Assets | 2.22B | 2.52B | 3.25B | 4.41B | 5.28B | 5.11B |
| Cash, Cash Equivalents and Short-Term Investments | 88.20M | 280.52M | 305.70M | 781.64M | 1.88B | 2.96B |
| Total Debt | 202.65M | 216.43M | 369.09M | 826.19M | 899.64M | 70.78M |
| Total Liabilities | 697.43M | 757.14M | 1.04B | 1.49B | 1.65B | 477.61M |
| Stockholders Equity | 1.53B | 1.76B | 2.21B | 2.92B | 3.61B | 4.55B |
Cash Flow | ||||||
| Free Cash Flow | -386.81M | -332.12M | -17.82M | -872.93M | -908.23M | -602.08M |
| Operating Cash Flow | -381.81M | -321.35M | 23.74M | -610.02M | -729.46M | -456.92M |
| Investing Cash Flow | 469.88M | 364.06M | -19.90M | -346.86M | -1.07B | -653.04M |
| Financing Cash Flow | -294.73M | -184.05M | -487.34M | -173.99M | 635.14M | 1.39B |
Venus Medtech (Hangzhou), Inc. Class H Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2500, the sentiment is Negative. The current price of 0.98 is below the 20-day moving average (MA) of 1.07, below the 50-day MA of 1.10, and below the 200-day MA of 1.70, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 35.10 is Neutral, neither overbought nor oversold. The STOCH value of 12.90 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2500.
Venus Medtech (Hangzhou), Inc. Class H Peers Comparison
Overall Rating
HK:660985Outperform
HK:223559Neutral
HK:216043Neutral- HK:250042Neutral
HK:225242Neutral
HK:085341Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:6609 | 85Outperform | HKD 2.18B | 18.16 | 7.90% | ― | 59.30% | 131.03% |
| HK:2235 | 59Neutral | HKD 2.82B | 27.65 | 4.08% | ― | 94.80% | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:2160 | 43Neutral | HKD 1.63B | -0.86 | -6.69% | ― | ― | ― |
| HK:2500 | 42Neutral | HKD 432.19M | -0.78 | -28.24% | ― | -38.15% | 25.70% |
| HK:2252 | 42Neutral | HKD 21.97B | -74.73 | -52.78% | ― | 114.97% | 63.21% |
| HK:0853 | 41Neutral | HKD 11.65B | 31.23 | 6.07% | ― | -3.62% | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:2500 | Venus Medtech (Hangzhou), Inc. Class H | 0.98 | -1.77 | -64.36% | |
| HK:0853 | MicroPort Scientific Corp | 6.08 | -5.92 | -49.33% | |
| HK:2160 | MicroPort CardioFlow Medtech Corp. | 1.28 | -4.67 | -78.49% | |
| HK:2235 | MicroTech Medical (Hangzhou) Co., Ltd. Class H | 6.70 | -0.20 | -2.90% | |
| HK:2252 | Shanghai MicroPort MedBot (Group) Co., Ltd. Class H | 21.18 | -5.94 | -21.90% | |
| HK:6609 | Shanghai Heartcare Medical Technology Corp. Ltd. Class H | 53.20 | -0.30 | -0.56% |
Venus Medtech (Hangzhou), Inc. Class H Corporate Events
Venus Medtech Shareholders Approve Capital-Raising Mandate at EGM
Shareholders of Venus Medtech (Hangzhou) Inc. have approved a special resolution at an extraordinary general meeting in Hangzhou, clearing the way for a new subscription of shares and convertible bonds. The meeting was validly convened under PRC law...
Venus Medtech Calls EGM to Approve Share and Bond Subscription Plan
Venus Medtech (Hangzhou) Inc. has called an extraordinary general meeting in Hangzhou on September 30, 2026, to seek shareholder approval for a subscription of new shares and convertible bonds under a subscription agreement. The company also plans to...
Venus Medtech Sets Extraordinary General Meeting for New Share and Bond Subscription
Venus Medtech (Hangzhou), Inc., a Hong Kong-listed Chinese medical technology company specializing in cardiovascular devices, maintains a diversified shareholder base across H shares and unlisted foreign shares. The firm is governed by a board that i...
Venus Medtech Plans Major Share and Convertible Bond Subscription
Venus Medtech (Hangzhou) Inc. has entered into a Subscription Agreement with an independent investor for a substantial capital injection via new shares and convertible bonds. The deal underscores the company’s continued effort to strengthen its...
Venus Medtech Interim Loss Widens as Revenue and Margins Decline
Venus Medtech (Hangzhou) Inc. reported a sharp deterioration in interim results for the six months ended June 30, 2026, as revenue fell 27.6% year on year to RMB135.5 million while gross profit dropped 32.2% to RMB93.5 million. The company’s lo...
Venus Medtech Schedules Board Meeting to Approve 2026 Interim Results
Venus Medtech (Hangzhou) Inc., a Hong Kong-listed medical technology company incorporated in the People’s Republic of China, is governed by a mixed board of executive, non-executive and independent non-executive directors, led by Executive Dire...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 22, 2026